Women who manage their attention-deficit/hyperactivity disorder with stimulants may experience worsening symptoms during certain stages of their menstrual cycle. A recent study published in the Journal of Attention Disorders tracked the daily symptom severity of adult women taking amphetamines. Follow-up data revealed that ADHD symptoms and negative mood peak during the menstrual period, indicating the need for individualized treatment plans that account for hormonal fluctuations.
Attention Deficit Hyperactivity Disorder affects approximately 6% of the adult population. This condition is characterized by chronic difficulty concentrating, increased impulsivity, and physical hyperactivity. Patients often have difficulty managing time, organizing daily tasks, and regulating emotional responses in demanding environments.
Historically, men were diagnosed at a much higher rate than women, often at a ratio of three boys to one girl. This diagnostic gap is steadily closing as clinicians become more aware of how this condition presents in adult women. Women often exhibit higher levels of inattention and internalized behaviors than superficial physical hyperactivity.
Because of this difference in symptom presentation, teachers and parents often miss warning signs in girls. Many women go undiagnosed throughout their childhood and only discover the cause of their lifelong struggles when they experience career or family burnout in adulthood.
Despite this increased diagnostic equivalence, female patients remain significantly underrepresented in the scientific literature. Researchers are just beginning to investigate how female-specific biological factors interact with disease. One universal aspect of female biology is the natural fluctuations in ovarian hormones such as estrogen and progesterone over the menstrual cycle.
Case reports and anecdotes sometimes suggest that these hormonal changes can influence both the severity of a patient’s symptoms and the effectiveness of medications. Some women report that their medications do not help them at all in the days leading up to their period, which seriously disrupts their work and social lives.
During the follicular phase, which begins after menstruation ends, estrogen levels gradually rise, reaching their peak at the time of ovulation. During the luteal phase, which occurs immediately after ovulation, both estrogen and progesterone are highly elevated. Both hormones then drop rapidly just before bleeding begins. Some previous studies in healthy women without neurodevelopmental disorders suggest that stimulants may be less effective during this late luteal phase.
Rebecca Zaritsky, a medical and doctoral student at Rutgers University, led a research team investigating whether these hormonal changes affect female patients undergoing active treatment for this disease. Her academic focus is on how biological factors influence neurodevelopment. Zaritsky collaborated with researchers Stephanie C. Reed and Suzette M. Evans of Columbia University and the New York State Psychiatric Institute. Their comprehensive expertise focuses on women’s health issues related to drug use and the menstrual cycle.
The research team designed the study to fill specific knowledge gaps regarding amphetamine salts prescribed to women. This category of drugs works by changing brain chemistry to improve concentration and includes widely known brand names such as Adderall and Mydais. In the United States, more than 60 percent of women of reproductive age being treated for this disease rely on amphetamine salts. The researchers wanted to see if the therapeutic effects of these daily medications varied with the menstrual cycle.
Researchers recruited adult women between the ages of 18 and 40 with regular menstrual cycles. All 30 final participants had a formal diagnosis of the disorder and were taking amphetamine salts most days of the week to manage their symptoms. Most participants reported receiving their first diagnosis in their mid-20s, reflecting a common delay in identifying symptoms among women. Participants also said they took medication almost every day, confirming how dependent they were on treatment.
To isolate the potential influence of natural hormonal cycles, this study excluded individuals taking hormonal oral contraceptives or other psychiatric medications. Participants agreed to complete an online survey every day for 35 consecutive days. This extended timeline was purposely chosen to collect data consistently over one complete menstrual cycle for all participants.
Each night, participants answered standard questions assessing their current mood and symptom severity. The researchers rated the frequency of 18 types of inattention and hyperactivity on a 4-point sliding scale ranging from rare to very frequent. They also reported their total daily drug doses in milligrams and recorded whether they were actively menstruating or menstruating.
Analysis of daily survey responses revealed clear patterns in symptom severity across months. Participants reported greater symptom severity during the menstrual period. Conversely, symptoms were mild during the mid-follicular phase. The difference in symptom onset between late luteal and mid-follicular phases was not statistically significant.
The team also assessed general psychological well-being alongside the main symptoms of the disorder. Participants reported increased negative mood during both the menstrual and late luteal phases compared to the mid-follicular phase. Negative mood changes were closely related to the severity of main symptoms.
Participants who reported a greater increase in negative mood during their period also recorded a greater increase in symptoms of attention and hyperactivity. The magnitude of this mood change served as a reliable predictor of the subjective experience of inattention. The patients who struggled the most with sadness and irritability were the same people who struggled the most with concentration.
The exact reason for this correspondence between mood and symptom severity remains to be determined. Decreased attention can naturally lead to low mood and emotional irritability. Alternatively, depression and physical fatigue may make it difficult for patients to manage the executive functions necessary for concentration. It is also possible that decreased estrogen levels trigger an integrated biological cascade that causes both depression and distraction at the same time.
Researchers initially hypothesized that patients might try to counteract these difficult menstrual periods by taking higher doses of prescribed stimulants. Survey data did not support this idea. The daily amphetamine dose remained completely constant throughout all stages of the cycle.
This lack of dose adjustment may reflect standard medical practice. Most prescribers do not recommend flexible, symptom-based dosing regimens for these highly regulated drugs. Patients may also be completely unaware that along with physical hormonal changes, the metabolism and effectiveness of the drug may be weakened.
The authors noted that there are several limitations to the interpretation of the data. The study relied entirely on self-report surveys from a relatively small group of 30 people. This reliance on remote self-reporting means that the objective accuracy of the data cannot be independently verified.
Self-report questionnaires also limit the ability to determine whether symptoms have objectively worsened or whether only afflicted participants perceive their symptoms to be worsening. The study protocol also did not include direct blood tests to confirm participants’ exact hormone levels.
Without tracking precise markers of estrogen and progesterone, researchers could only approximate the hormonal environment in the body based on the normal timing of human menstruation. Researchers were unable to study other interesting and unique times, such as the exact moment of peak fertility immediately after ovulation.
Additionally, excluding participants who are overcoming concurrent mood disorders or taking hormonal contraceptives limits the applicability of these results to the general public. Future studies featuring more participants and direct medical observations may help reveal how hormones interact with brain chemistry and prescribed medications. Expanding the scope to women going through adolescence, pregnancy, and menopause could provide a more thorough understanding of women’s experiences.
Although varied and expanded data are pending, the new findings suggest alternative types of clinical interventions that may ultimately improve the daily lives of female patients. Educational efforts could help women schedule demanding tasks around days when they feel most capable. Clinicians may also explore alternative prescribing strategies that temporarily increase the stimulant dose during certain menstrual periods to counteract the decrease in drug efficacy.
If these symptom fluctuations continue to cause distress, clinicians may eventually consider broader pharmacological interventions. Some patients may benefit from taking oral contraceptives to reduce the natural hormonal fluctuations that cause a spike in symptoms. Some people find relief from targeted use of antidepressants to improve negative mood disruptions during specific cycle stages. Each of these potential interventions requires extensive future research to confirm its effectiveness and safety.
The study, “ADHD Symptoms and Mood Changes Across the Menstrual Cycle in Women Treated with Stimulants: A Pilot Study,” was authored by Rebecca Zaritsky, Stephanie C. Reed, and Suzette M. Evans.
